On Monday, Following Stocks were among the “Top 100 Losers” of U.S. Stock Market: Celldex Therapeutics, Inc. (NASDAQ:CLDX), Isis Pharmaceuticals, Inc. (NASDAQ:ISIS), Intrexon Corporation (NYSE:XON), PDC Energy, Inc. (NASDAQ:PDCE)
Celldex Therapeutics, Inc. (NASDAQ:CLDX), with shares declined -6.09%, closed at $28.53.
Isis Pharmaceuticals, Inc. (NASDAQ:ISIS), with shares dropped -5.92%, settled at $69.23.
Intrexon Corporation (NYSE:XON),with shares dipped -5.27%, and closed at $43.68.
PDC Energy, Inc. (NASDAQ:PDCE), plummeted -2.39%, and closed at $51.07.
Latest NEWS regarding these Stocks are depicted underneath:
Celldex Therapeutics, Inc. (NASDAQ:CLDX)
Celldex Therapeutics, Inc. (CLDX), declared that it has reached a clinical trial partnership with Roche to evaluate the safety, tolerability and preliminary efficacy of varlilumab, Celldex’s CD27 targeting investigational antibody, and MPDL3280A (anti-PDL1), Roche’s investigational cancer immunotherapy in a Phase 1/2 study in renal cell carcinoma.
Varlilumab and MPDL3280A are part of a new class of investigational medicines known as cancer immunotherapies that are designed to harness the body’s own immune system to fight cancer through separate yet complementary mechanisms of action that may enable the activation of T cells, restoring their ability to effectively detect and attack tumor cells. Preclinical data suggest the combination of these two mechanisms are synergistic and may enhance anti-tumor immune response contrast to either agent alone. In Celldex’s Phase 1 study of varlilumab in multiple solid tumors, promising signs of clinical activity in patients with refractory renal cell carcinoma were observed, counting a durable partial response (11.0+ months) that has continued to decrease in tumor volume over time and prolonged stable disease (4 patients with a range of 5.3 to 30.7+ months).
Under the terms of this contract, Roche will provide study drug and Celldex will be responsible for conducting and funding the study, which is predictable to start in 2015.
Varlilumab is a fully human monoclonal antibody that targets CD27, a critical molecule in the activation pathway of lymphocytes. CD27 can be effectively manipulated with activating antibodies to induce potent anti-tumor responses and may result in fewer toxicities due to its restricted expression and regulation. Varlilumab is a potent anti-CD27 agonist that induces activation and proliferation of human T cells when combined with T cell receptor stimulation.
Celldex Therapeutics, Inc., a biopharmaceutical corporation, develops, manufactures, and commercializes novel therapeutics for human health care in the United States. The corporation’s lead drug candidates comprise rindopepimut (CDX-110), a targeted immunotherapeutic in a pivotal Phase III study for the treatment of front-line glioblastoma, in addition to in Phase II study for the treatment of recurrent glioblastoma; and Glembatumumab vedotin (CDX-011), a targeted antibody-drug conjugate in a randomized Phase IIb study for the treatment of triple negative breast cancer, in addition to in Phase II study for the treatment of metastatic melanoma.
Isis Pharmaceuticals, Inc. (NASDAQ:ISIS)
Isis Pharmaceuticals, Inc. (ISIS), declared positive results from a Phase 1 study with ISIS-ANGPTL3Rx. In this study, healthy volunteers treated with ISIS-ANGPTL3Rx achieved dose-dependent, statistically noteworthy reductions in angiopoietin-like 3 (ANGPTL3) of up to 93 percent with a mean reduction of up to 84 percent from baseline (prd European Atherosclerosis Society in Glasgow, United Kingdom.
The Phase 1 study of ISIS-ANGPTL3Rx was a blinded, placebo-controlled, dose-escalation study in healthy volunteers. The study was designed to assess the safety, tolerability and pharmacokinetics of ISIS-ANGPTL3Rx. ISIS-ANGPTL3Rx was evaluated in single and multiple doses ranging from 50 mg per week up to 400 mg per week for the single dose and 100 mg per week up to 400 mg per week for the multiple dose. In this study, ISIS-ANGPTL3Rx was generally well tolerated.
ISIS-ANGPTL3Rx is an antisense drug designed to reduce ANGPTL3. ANGPTL3 is produced in the liver and regulates lipid, glucose and energy metabolism. In preclinical studies, antisense inhibition of ANGPTL3 resulted in robust reductions of multiple lipid parameters, counting total-cholesterol, and triglycerides. ISIS-ANGPTL3Rx is part of Isis’ lipid franchise and, as such, Akcea Therapeutics, Isis’ wholly owned partner, is responsible for developing ISIS-ANGPTL3Rx.
Isis Pharmaceuticals, Inc. engages in the discovery and development of antisense drugs using novel drug discovery platform. The corporation’s flagship product comprises the KYNAMRO injection, which is an apo-B synthesis inhibitor for patients with homozygous familial hypercholesterolemia; and for the reduction of low-density lipoprotein cholesterol.
Intrexon Corporation (NYSE:XON)
Working in partnership with Intrexon Corporation (XON), a leader in synthetic biology, Fibrocell Science, Inc. (FCSC), declared the appointment of Keith A. Goldan as Senior Vice President and Chief Financial Officer (CFO), effective right away. Mr. Goldan offers more than 20 years of executive finance and operational leadership in biopharmaceutical and medical technology companies.
Preceding to joining Fibrocell, Mr. Goldan served as CFO of two publicly traded companies. Most recently he served as Senior Vice President and CFO of NuPathe Inc., a NASDAQ-listed specialty pharmaceutical corporation that was attaind by Teva Pharmaceutical Industries Ltd. in 2014. Preceding to joining NuPathe Inc., Mr. Goldan was CFO and a member of the board of directors of PuriCore plc, a medical technology corporation listed on the London Stock Exchange, and Vice President and CFO of Biosyn, Inc., a specialty pharmaceutical corporation. Mr. Goldan formerly served in a variety of roles with ViroPharma Incorporated, Century Capital Associates—a specialty consulting firm with a focus on capital strategy for healthcare clients—and the Healthcare & Life Sciences Practice of KPMG, LLP. Mr. Goldan earned a B.S. in Finance from the Robert H. Smith School of Business at the University of Maryland and an M.B.A. from The Wharton School at the University of Pennsylvania.
Fibrocell Science, Inc. (FCSC) is an autologous cell therapy corporation primarily focused on developing first-in-class treatments for rare and serious skin and connective tissue diseases with high unmet medical needs.
Intrexon Corporation, a biotechnology corporation, operates in the synthetic biology field in the United States. The corporation, through a suite of proprietary and complementary technologies, designs, builds, and regulates gene programs, which are DNA sequences that comprise of key genetic components.
PDC Energy, Inc. (NASDAQ:PDCE)
PDC Energy, Inc. (PDCE), declared that it has closed its formerly declared underwritten public offering of 4,002,000 shares. The net proceeds from the offering were about $203 million after deducting underwriters’ compensation (but before estimated expenses). Goldman, Sachs & Co. and J.P. Morgan Securities LLC acted as the sole underwriters of the offering.
The offering was made following an effective shelf registration statement formerly filed with the Securities and Exchange Commission. The offering was made by means of a prospectus supplement and the accompanying prospectus, copies of which may be obtained by sending a request to: Goldman, Sachs & Co., 200 West Street, New York, New York 10282, Attn: Prospectus Department, email: [email protected]; J.P. Morgan Securities LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, New York 11717, email: [email protected].
PDC Energy, Inc., an independent exploration and production company, acquires, explores for, develops, and produces crude oil, natural gas, and natural gas liquids in the United States. The company operates in two segments: Oil and Gas Exploration and Production, and Gas Marketing.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
